

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/647,358
Filing Date	August 25, 2003
First Named Inventor	Charles L. Bisgaier, et al
Art Unit	1616
Examiner Name	John Pak
Attorney Docket Number	PC17370

Sheet	2	of	2
-------	---	----	---

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		AVIRAM, et al., "Interaction of Oxidized Low Density Lipoprotein with Macrophages in Atherosclerosis, and the Antithrombotic/Antioxidant", Eur J Clin Chem Clin Biochem, 1996, pp 699-698, Vol. 34	
		GRUNDY S. M., et al., "Atherogenic Dyslipidemia: Lipoprotein Abnormalities and Implications for Therapy", Amer J Cardiology, 1995, Vol. 75, pp 45B-52B	
		HEINONEN T. M., et al., "Atorvastatin, a New HMG-CoA Reductase Inhibitor as Monotherapy and Combined With Colestipol", J Cardio Pharm Therap, 1996, pp 117-122, Vol.1, No.2	
		ILLINGWORTH D. R., et al., "Comparative Effects of Lovastatin and Nicin in Primary Hypercholesterolemia", Arch Internal Med, 1994, pp 1586-1595, Vol.154, No.14	
		JONES P. H., et al., "Effect of gemfibrozil on level of lipoprotein (a) in Type II hyperlipoproteinemic subject, J Lipid Res, 1996, pp 1298-1308, Vol. 37	
		SHIOMI M., et al., "Suppression of established atherosclerosis and xanthomas in mature Wistar-Kyoto (WKY) rabbits by keeping their serum cholesterol levels extremely low", Atherosclerosis, 1990, pp 69-80, Vol.83	
		STONE N. J., et al., "Lipid Management: Current Diet and Drug Treatment Options," Amer J Med, 1996, pp 4A4CS-4A49S, Vol.101 (suppl 4A)	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP §909. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9198 (1-800-785-9199) and select option 2.